BioScrip Company Profile (NASDAQ:BIOS)

BioScrip trades on the NASDAQ under the ticker symbol "BIOS."

BioScrip, Inc. (NASDAQ:BIOS) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.01. The firm earned $218.11 million during the quarter, compared to analyst estimates of $220.05 million. The firm's revenue was down 6.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.14) earnings per share. View BioScrip's Earnings History.

BioScrip is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for BioScrip.

4 equities research analysts have issued 1-year price targets for BioScrip's shares. Their forecasts range from $3.50 to $4.50. On average, they expect BioScrip's stock price to reach $3.94 in the next year. View Analyst Ratings for BioScrip.

Here are some recent quotes from research analysts about BioScrip stock:

• 1. According to Zacks Investment Research, "BioScrip exited the second quarter on a dismal note with revenues missing the Zacks Consensus Estimate and adjusted net loss wider-than-expected. Management’s unimpressive 2017 guidance, which includes the negative impact of the Cures Act legislation, also adds to our concerns. Nonetheless, the market is upbeat about BioScrip’s announcement to continue to offer certain core product lines to UnitedHealthcare. We are encouraged by the company’s recent progress, courtesy of its new multi-faceted CORE plan which was adopted to improve the financial position. Further, the company achieved annualized supply chain improvement of roughly $20 million since the acquisition of Home Solutions. Over the last three months, BioScrip has been trading above the broader industry." (8/14/2017)
• 2. Jefferies Group LLC analysts commented, "We are incrementally more positive on BIOS following better-than-expected 4Q results. Growth in Core revenues is progressing according to plan & expense initiatives should offset a majority of the headwind from the 21st Century Cures Act. Accelerating EBITDA growth throughout 2017 should provide investors with increasing confidence in BIOS ability to reduce debt leverage to more normalized levels (~6x) by YE17 & put BIOS on a path to >$80MM of EBITDA in 2018." (3/6/2017)

BioScrip saw a decrease in short interest in the month of August. As of August 31st, there was short interest totalling 18,783,163 shares, a decrease of 11.6% from the August 15th total of 21,241,640 shares. Based on an average daily trading volume, of 2,028,727 shares, the days-to-cover ratio is currently 9.3 days. Currently, 14.8% of the shares of the company are short sold.

Some companies that are related to BioScrip include AC Immune SA (ACIU), Meridian Bioscience (VIVO), Synergy Pharmaceuticals (SGYP), ANI Pharmaceuticals (ANIP), Tactile Systems Technology (TCMD), ImmunoGen (IMGN), Calithera Biosciences (CALA), SciClone Pharmaceuticals (SCLN), ARGENX SE-ADR (ARGX), Triple-S Management Corporation (GTS), Mesa Laboratories (MLAB), Achillion Pharmaceuticals (ACHN), Inovio Pharmaceuticals (INO), Sucampo Pharmaceuticals (SCMP), Aurinia Pharmaceuticals (AUPH), Assembly Biosciences (ASMB), Karyopharm Therapeutics (KPTI) and GenMark Diagnostics (GNMK).

BioScrip's management team includes the folowing people:

• Daniel E. Greenleaf, President, Chief Executive Officer, Director
• Stephen M. Deitsch, Chief Financial Officer, Senior Vice President, Treasurer
• David Evans, Chief Operating Officer, Senior Vice President
• Betty Y Jang, Senior Vice President, Chief Compliance Officer
• C. Britt Jeffcoat, Chief Accounting Officer, Vice President, Controller
• Kathryn M. Stalmack, General Counsel
• Scott J. Davido, Chief Implementation Officer
• Michael G. Bronfein CPA, Director
• Steven Neumann, Director
• Christopher S. Shackelton, Director

BioScrip's stock is owned by many different of retail and institutional investors. Top institutional shareholders include COLISEUM CAPITAL MANAGEMENT, LLC (16.50%), COLISEUM CAPITAL MANAGEMENT, LLC (14.60%), Gilder Gagnon Howe & Co. LLC (12.57%), GAMCO INVESTORS, INC. ET AL (10.37%), ARES MANAGEMENT LLC (9.20%) and GAMCO INVESTORS, INC. ET AL (9.19%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger, Michael G Bronfein and R Carter Pate. View Institutional Ownership Trends for BioScrip.

BioScrip's stock was sold by a variety of institutional investors in the last quarter, including Diamond Hill Capital Management Inc., Perkins Capital Management Inc., Virtu KCG Holdings LLC, California Public Employees Retirement System, Gamco Investors INC. ET AL, Marathon Capital Management, California State Teachers Retirement System and Parametric Portfolio Associates LLC. Company insiders that have sold BioScrip stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.

BioScrip's stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, Alta Fundamental Advisers LLC, FMR LLC, Roanoke Asset Management Corp NY, State Street Corp, Vanguard Group Inc., Benchmark Capital Advisors and Northern Trust Corp. Company insiders that have bought BioScrip stock in the last two years include Coliseum Capital Management, L, Daniel E Greenleaf, David W Golding, Jeffrey M Kreger and R Carter Pate. View Insider Buying and Selling for BioScrip.

Shares of BioScrip can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of BioScrip stock can currently be purchased for approximately $2.40.